ARTICLE | Clinical News

Pegasys peginterferon alfa-2a: Phase III data; NDA under review

December 11, 2000 8:00 AM UTC

Researchers published in The New England Journal of Medicine previously reported results of a 531-patient open-label international Phase III study comparing 180 ug Pegasys once weekly to interferon alfa-2a three times per week, showing that sustained virologic responses were 39 and 19 percent, respectively, following 48 weeks of treatment and a 24-week follow-up period (p=0.001) (see BioCentury, April 24). At week 48, virologic response was 69 and 28 percent for the Pegasys and interferon alfa-2a groups, respectively (p=0.001). ...